CURE

A Breast Cancer Survivor’s First Brush with Skin Cancer

Breast cancer survivors face increased skin cancer risk, necessitating regular dermatological check-ups and self-examinations ...
The American Journal of Managed Care

Optimizing Nonsurgical Management of Skin Tumors at Maui Derm 2026

Speakers delved into innovative strategies in skin tumor management, focusing on chemotherapies, patient risk assessment, and evolving treatment protocols.
TMCnet

Last Patient Completes Biofrontera's Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities

WOBURN, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...
dermatologyadvisor

Potassium Hydroxide 5% Is Superior to Diclofenac 3% for Actinic Keratosis

Treatment with potassium hydroxide 5% solution among patients with actinic keratosis was associated with greater complete clearance rates and faster onset of action compared with diclofenac 3% gel and ...
SciELO

Prevalence and factors associated with actinic keratosis in 1346 patients attending at a public dermatology service: a cross-sectional study

BACKGROUND: Actinic keratosis is a common preneoplastic dermatosis and is the third most common reason for dermatological consultations. Identifying the associated factors, diagnosis, and early ...
Morningstar

Bimiralisib, Topical PI3K/mTOR Inhibitor Shows Up To 92% Clearance Rate And Superior Tolerability In Proof-Of-Concept Actinic Keratosis Study

Torqur AG, subsidiary of Swiss Rockets incubator and a clinical-stage company advancing targeted therapies in oncodermatology and oncology, announced the results of the full Phase 2 proof-of-concept ...